Bhupinder Singh

Company: Renibus Therapeutics

Job title: Chief Medical Officer

Seminars:

Repositioning AKI at the Forefront of R&D: Targeting Complex Pathophysiology, Overcoming Heterogeneity & Enhancing Return on Investment 11:00 am

The heterogeneity across phenotypic subtypes has made AKI significantly difficult to study, therefore making progress of new specific treatments and disease management rather stagnant in recent years. From balancing the need for AKI resolution while minimizing long-term kidney damage, to addressing AKI subtypes with medical interventions that target specific underlying causes, tackle key questions with…Read more

day: Pre-Conference Workshop Day